Follow
Kwok-Kin Wong
Kwok-Kin Wong
NYU Langone Health
Verified email at nyulangone.org
Title
Cited by
Cited by
Year
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi, S Maheswaran, ...
Cell 141 (1), 69-80, 2010
22982010
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
CH Yun, KE Mengwasser, AV Toms, MS Woo, H Greulich, KK Wong, ...
Proceedings of the National Academy of Sciences 105 (6), 2070-2075, 2008
20432008
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, LR Chirieac, ...
Oncogene 27 (34), 4702-4711, 2008
15232008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
JA Engelman, L Chen, X Tan, K Crosby, AR Guimaraes, R Upadhyay, ...
Nature medicine 14 (12), 1351-1356, 2008
15102008
Non-small-cell lung cancers: a heterogeneous set of diseases
Z Chen, CM Fillmore, PS Hammerman, CF Kim, KK Wong
Nature Reviews Cancer 14 (8), 535-546, 2014
14072014
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ...
Science 343 (6168), 305-309, 2014
12462014
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 10501, 2016
11762016
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsImmune Escape of EGFR-Mutant Tumors through PD-1
EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ...
Cancer discovery 3 (12), 1355-1363, 2013
11472013
High-throughput oncogene mutation profiling in human cancer
RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ...
Nature genetics 39 (3), 347-351, 2007
11242007
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
J Luo, MJ Emanuele, D Li, CJ Creighton, MR Schlabach, TF Westbrook, ...
Cell 137 (5), 835-848, 2009
11112009
LKB1 modulates lung cancer differentiation and metastasis
H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ...
Nature 448 (7155), 807-810, 2007
10972007
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ...
Nature 462 (7276), 1070-1074, 2009
10882009
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
AJ Bass, H Watanabe, CH Mermel, S Yu, S Perner, RG Verhaak, SY Kim, ...
Nature genetics 41 (11), 1238-1242, 2009
9912009
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
9412018
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ...
Cancer cell 23 (5), 677-692, 2013
7982013
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ...
Cancer research 67 (24), 11924-11932, 2007
7792007
Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth
AMG Houghton, DM Rzymkiewicz, H Ji, AD Gregory, EE Egea, HE Metz, ...
Nature medicine 16 (2), 219-223, 2010
7142010
Targeting the PI3K signaling pathway in cancer
KK Wong, JA Engelman, LC Cantley
Current opinion in genetics & development 20 (1), 87-90, 2010
6772010
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsResistance Mechanisms in ALK Kinase Inhibitors
T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ...
Cancer research 71 (18), 6051-6060, 2011
6402011
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCo-occurring …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
6332015
The system can't perform the operation now. Try again later.
Articles 1–20